stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Return on equity
Sanofi's return on equity over the twelve months to 30 September 2026 was 0.00%, down 10.7 percentage points from fiscal 2025 (10.7%). Over the past ten years it has ranged from 4.62% (fiscal 2019) to 20.3% (fiscal 2020); the current reading is higher than 73% of that period. That is below the Drug Manufacturers General industry median of 5.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 10.7% | 3.38 |
| FY2024 | 7.31% | (0.01) |
| FY2023 | 7.32% | (3.65) |
| FY2022 | 11.0% | 1.40 |
| FY2021 | 9.57% | (10.77) |
| FY2020 | 20.3% | 15.72 |
| FY2019 | 4.62% | (2.88) |
| FY2018 | 7.50% | (7.20) |
| FY2017 | 14.7% | 6.59 |
| FY2016 | 8.11% | 1.28 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 78.4% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company compare | 44.0% |
| GSK GSK PLC Sponsored ADR compare | 25.5% |
| NVS Novartis AG compare | 24.4% |
| AZN AstraZeneca PLC compare | 22.6% |
| PFE Pfizer Inc. compare | 4.42% |
| SNY Sanofi | 0.00% |
| GILD Gilead Sciences, Inc. compare | −22.5% |
| Drug Manufacturers General industry median | 5.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement